Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
184 hedge funds and large institutions have $761M invested in Acorda Therapeutics in 2019 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 79 increasing their positions, 41 reducing their positions, and 21 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 41
24% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 21
3% more funds holding
Funds holding: 179 → 184 (+5)
8% less capital invested
Capital invested by funds: $826M → $761M (-$65M)
52% less call options, than puts
Call options by funds: $2.4M | Put options by funds: $5.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$27.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.6M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$6.06M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$5.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$17.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$17.1M |
| 3 |
SCM
Scopia Capital Management
New York
|
-$15.5M |
| 4 |
Millennium Management
New York
|
-$11M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.28M |
ACOR Hedge Fund Activity: Q1 2019 in Review
184 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2019, worth a combined $761M — down 7.9% from $826M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ACOR positions and 21 closed out — a net gain of 5 holders — while 79 added to existing stakes and 41 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $27.4M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $17.3M sold.
- 184 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2019, up from 179 in Q4 2018.
- Funds reported $761M of Acorda Therapeutics stock for Q1 2019, down 7.9% quarter-over-quarter.
- 26 funds opened new Acorda Therapeutics positions in Q1 2019 and 21 closed out, a net change of +5 holders.
- The largest Acorda Therapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $27.4M added.
- The largest Acorda Therapeutics seller in Q1 2019 was PFM Health Sciences, an estimated $17.3M sold.
Based on aggregated 13F filings for Q1 2019.